Event Type
Disclosure
Mandatory
Variant
8-K
Entry Into a Material Definitive Agreement. On February 26, 2026, Kymera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “TD Cowen Sales
Termination of a Material Definitive Agreement. On February 26, 2026, Jefferies LLC (“Jefferies”) acknowledged and accepted the Company’s prior written notice t
Other Events. Pursuant to the terms of the Registration Rights Agreement, dated as of June 26, 2025, by and among the Company, Baker Brothers Life Sciences, L.P
. Exhibits (d) Exhibits Exhibit No. Description 5.1 Opinion of Goodwin Procter LLP. 5.2 Opinion of Goodwin Procter LLP. 10.1 Sales Agreement, by and between Kym